260 related articles for article (PubMed ID: 34470936)
1. [Pharmacological properties and clinical outcomes of the anti-cancer drug, cabozantinib (CABOMETYX
Osaka T; Yamaguchi N; Hara T
Nihon Yakurigaku Zasshi; 2021; 156(5):303-311. PubMed ID: 34470936
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Markham A
Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
Kelley RK; W Oliver J; Hazra S; Benzaghou F; Yau T; Cheng AL; Rimassa L
Future Oncol; 2020 Jul; 16(21):1525-1536. PubMed ID: 32491932
[TBL] [Abstract][Full Text] [Related]
5. [Cabozantinib: Mechanism of action, efficacy and indications].
Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
[TBL] [Abstract][Full Text] [Related]
6. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib Approved for Renal Cell Carcinoma.
Cancer Discov; 2016 Jun; 6(6):OF3. PubMed ID: 27150533
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review.
Graham J; Vogel A; Cheng AL; Bjarnason GA; Neal JW
Cancer Treat Rev; 2022 Nov; 110():102453. PubMed ID: 36037792
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
Al-Salama ZT; Keating GM
Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
[TBL] [Abstract][Full Text] [Related]
12. Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial.
Rosellini M; Tassinari E; Marchetti A; Mollica V; Massari F
Eur Urol; 2024 Jan; 85(1):97-98. PubMed ID: 37777426
[No Abstract] [Full Text] [Related]
13. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
14. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Borkowetz A; Sommer U; Baretton G; Gruellich C; Bürk BT; Erb HHH; Thomas C;
World J Urol; 2024 Feb; 42(1):94. PubMed ID: 38386122
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence.
Santoni M; Iacovelli R; Colonna V; Klinz S; Mauri G; Nuti M
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1029-1054. PubMed ID: 34445927
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib for the treatment of kidney cancer.
Abdelaziz A; Vaishampayan U
Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib: An evolving therapy for hepatocellular carcinoma.
El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK
Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957
[TBL] [Abstract][Full Text] [Related]
20. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
